11 assets in ALK-Negative Anaplastic Large Cell Lymphoma

Therapeutic assets addressing ALK-Negative Anaplastic Large Cell Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
(+)-Vincristine ALK-Negative Anaplastic Large Cell Lymphoma	Shanghai Jiao Tong University School of Medicine	P4	BBB (72)
Adriamycin ALK-Negative Anaplastic Large Cell Lymphoma	City of Hope Medical Center	P4	BB (70)
Etoposide ALK-Negative Anaplastic Large Cell Lymphoma	City of Hope Medical Center	P4	BB (70)
Prednisone ALK-Negative Anaplastic Large Cell Lymphoma	Shanghai Jiao Tong University School of Medicine	P4	BB (70)
Cyclophosphamide ALK-Negative Anaplastic Large Cell Lymphoma	Shanghai Jiao Tong University School of Medicine	P4	BB (69)
Aclarubicin ALK-Negative Anaplastic Large Cell Lymphoma	Shanghai Jiao Tong University School of Medicine	P2	CCC (53)
Brentuximab Vedotin ALK-Negative Anaplastic Large Cell Lymphoma	City of Hope Medical Center	P2	CCC (53)
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE ALK-Negative Anaplastic Large Cell Lymphoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab ALK-Negative Anaplastic Large Cell Lymphoma	National Cancer Institute (NCI)	P2	CCC (53)
Ro-Choep-21 ALK-Negative Anaplastic Large Cell Lymphoma	Fondazione Italiana Linfomi - ETS	P1/2	CCC (48)
c7r.cd30.car-ebvst cells ALK-Negative Anaplastic Large Cell Lymphoma	Baylor College of Medicine	P1	CC (43)